U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): ~~March~~April 8 2013

SafeCode Drug Technologies Corp

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

	99-0362482
(Commission File No.)	(IRS Employer Identification No.)

c/o Joel Klopfer

6 Meever Hamiltah Street

Jerusalem 97761, Israel

(Address and telephone number of principal executive offices and place of business)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 35.02 ~~Unregistered~~DEPARTURES ~~Sales~~OF ofDIRECTORS ~~Equity~~OR ~~Securities~~PRINCIPAL OFFICERS; ELECTION OF DIRECTORS, APPOINTMENT OF PRINCIPAL OFFICERS

On ~~March~~April 8 2013, ~~the~~SafeCode ~~Registrant~~Drug ~~issued~~Technologies aCorp accepted ~~total~~the resignation of 20Joel Klopfer as President,~~000,000~~ ~~shares~~CEO ofand ~~additional~~a ~~common~~director. ~~stock~~There ofwas no disagreement by Mr. Klopfer with the ~~Issuer~~Company regarding its operations, topolicies ~~Itamar~~or ~~Zer~~practices. ~~CFO~~Mr. ~~and~~Akiva ~~Secretary~~Schonfled of, ~~the~~has ~~Issuer~~been ~~. The shares~~appointed by the Board of ~~common~~Directors ~~stock~~to ~~were~~also ~~issued~~serve as ~~2013~~the Company's ~~compensation~~interim CEO.

~~The~~Item ~~shares~~9.01 ~~were~~Financial ~~issued~~Statements ~~without~~and ~~registration under Section 5 of the Securities Act of 1933 in reliance on the exemption from registration contained in Section 4(2) of the Securities Act~~Exhibits.

~~Section~~(b) 5The following documents are filed as exhibits to this report on Form 8--K ~~Corporate~~or ~~Governance~~incorporated ~~and~~by reference herein. Any document incorporated by reference is identified by a parenthetical reference ~~Management~~to the SEC filing that included such document.

Item 5.03 Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.

Exhibit No.		Description
17.1		Letter of Resignation of Joel Klopfer , dated April 8 2013 , filed herewith.

On or about April 1 2012 , the Company received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50.1 % of the total issued and outstanding shares of voting stock of the Company approving a Certificate of Amendment to the Certificate of Incorporation of the Company, pursuant to which the Company will change , increase the authorized capital of the Company to a total of 1,000,000,000 shares of common stock with a par value of $0.0001 per share.SIGNATURES

~~The~~Pursuant ~~Company~~to ~~however only or about March 5 2013 , filed with~~ the ~~Secretary~~requirements of the ~~State~~Securities Exchange Act of ~~Delaware~~1934, ~~to increase~~ the ~~authorized~~Registrant ~~capital~~has ofduly ~~the~~caused ~~Corporation~~this report to be ~~1,000,000,000 shares of~~signed ~~common~~on ~~stock,~~its ~~par~~behalf ~~value~~by ofthe $0undersigned hereunto duly authorized.~~0001.~~

~~SIGNATURES~~/s/ Akiva Shonfled

~~Pursuant~~Director toand ~~the~~Interim ~~requirements of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~CEO

Dated: ~~March~~April 118 2013

	Medisafe 1 Technologies Corp.
	By:	Joel Klopfer
		Joel Klopfer
		Title: President and Director (Principal Executive Officer)

Filing Compare · SAFECODE DRUG TECHNOLOGIES CORP.